Turkey Pharmaceutical Market Valued at USD 22.3 Billion, Expected to Reach USD 32.6 Billion by 2034

As per IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Turkey pharmaceutical market size reached USD 22.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 32.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.19% during 2026-2034. The market is primarily driven by the expanding healthcare sector, improving access to healthcare services, rising demand from the growing geriatric population, advancements in medical technology, increasing adoption of biologics and biosimilars, and strategic investments by domestic and international pharmaceutical companies.

The market is experiencing strong development momentum as Turkey strengthens its healthcare infrastructure, domestic manufacturing capabilities, biotechnology ecosystem, and pharmaceutical export base. The country's pharmaceutical industry encompasses around 820 companies, more than 109 pharmaceutical and radiopharmaceutical production facilities, and over 50,000 employees. Turkish pharmaceutical manufacturers also export products to more than 186 countries, strengthening the country's role as a regional pharmaceutical manufacturing and distribution hub.

How AI is Reshaping the Future of the Turkey Pharmaceutical Market?

• AI-Powered Drug Discovery and Research: Artificial intelligence is helping pharmaceutical companies analyze large biological and clinical datasets, identify potential drug candidates, predict molecular interactions, and accelerate early-stage research. Turkey's expanding R&D infrastructure creates opportunities for AI-enabled drug discovery, particularly in biotechnology, oncology, rare diseases, and biosimilar development.
• Intelligent Manufacturing and Quality Control: AI-powered computer vision, predictive maintenance, and automated process monitoring can help pharmaceutical manufacturers improve production consistency, identify defects, optimize equipment utilization, and strengthen compliance with stringent quality standards. Turkey's manufacturing base includes facilities operating according to international standards, creating a strong environment for advanced pharmaceutical manufacturing technologies.
• AI-Driven Personalized Healthcare and Demand Analytics: Pharmaceutical companies can use AI to analyze prescription patterns, patient data, treatment outcomes, and healthcare utilization trends to identify unmet medical needs and optimize product strategies. These capabilities can support personalized treatment approaches while helping manufacturers and distributors improve inventory planning and pharmaceutical supply chains.

Request for a Sample Report for Detailed Evaluation: https://www.imarcgroup.com/turkey-pharmaceutical-market/requestsample

Turkey Pharmaceutical Market Trends and Drivers:

The Turkey pharmaceutical market is witnessing sustained expansion supported by increasing healthcare accessibility, demographic changes, domestic manufacturing development, biotechnology investments, and growing demand for innovative therapies. Turkey's healthcare transformation initiatives have strengthened the country's healthcare ecosystem, while pharmaceutical production capabilities continue to expand across conventional drugs, biologics, vaccines, and specialized therapies.

The growing geriatric population represents an important demand driver for the pharmaceutical industry. Turkey's population aged 65 and above reached 8.45 million, representing 9.9% of the total population according to available demographic statistics. The share of older people is expected to increase considerably over the coming decades, creating greater demand for medicines used in cardiovascular diseases, diabetes, musculoskeletal disorders, oncology, and other chronic conditions.

Increasing pharmaceutical production and healthcare expenditure are also supporting market development. The Turkish pharmaceutical market reached TRY 324.6 Billion in value and approximately 2.57 Billion boxes in volume, according to industry data. The hospital channel accounted for 12.8% of market value and 8.5% of volume, highlighting the important role of institutional healthcare procurement alongside pharmacy sales.

Biotechnology and biosimilars are becoming increasingly important areas of opportunity. Biotechnological products represented 18.8% of prescription products by value, corresponding to approximately TRY 60.9 Billion across around 40 million units. The development of domestic biotechnology capabilities is helping Turkey reduce reliance on imported high-value therapies while creating opportunities for technology transfer and international collaboration.

Government investment incentives are further supporting pharmaceutical manufacturing, R&D, and technology-intensive projects. Turkey's investment incentive framework includes strategic incentives, technology incentives, R&D and design center support, tax advantages, employment support, and customized project-based incentives. The HIT-30 program provides tailor-made support for large-scale strategic investments, while R&D expenditures can qualify for tax deductions under applicable programs.

The country's export-oriented pharmaceutical ecosystem is another major growth opportunity. Pharmaceutical exports reached approximately USD 2.5 Billion, while World Bank trade data indicates pharmaceutical product exports of around USD 2.46 Billion. South Korea and Hungary were among the leading destinations, followed by markets including Georgia, Iraq, Iran, Cyprus, Poland, Azerbaijan, and Germany.

Connect for Detailed Segmentation Analysis - Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=24198&flag=E

Turkey Pharmaceutical Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Type:

• Pharmaceutical Drugs
• Cardiovascular Drugs
• Dermatology Drugs
• Gastrointestinal Drugs
• Genito-Urinary Drugs
• Hematology Drugs
• Anti-Infective Drugs
• Metabolic Disorder Drugs
• Musculoskeletal Disorder Drugs
• Central Nervous System Drugs
• Oncology Drugs
• Ophthalmology Drugs
• Respiratory Diseases Drugs
• Biologics
• Monoclonal Antibodies
• Therapeutic Proteins
• Vaccines

Pharmaceutical drugs represent a major component of the Turkey pharmaceutical market, supported by broad demand across cardiovascular, metabolic, respiratory, gastrointestinal, neurological, and infectious disease treatments. At the same time, biologics are becoming increasingly significant as pharmaceutical manufacturers invest in monoclonal antibodies, therapeutic proteins, vaccines, and biosimilar technologies.

Breakup By Nature:

• Organic
• Conventional

Conventional pharmaceutical products account for a significant portion of the market, supported by established manufacturing infrastructure, widespread therapeutic applications, and extensive distribution networks. Meanwhile, organic and naturally positioned pharmaceutical products are gaining attention as consumers and healthcare stakeholders increasingly focus on wellness, preventative healthcare, and alternative therapeutic approaches.

Breakup By Region:

• Marmara
• Central Anatolia
• Mediterranean
• Aegean
• Southeastern Anatolia
• Black Sea
• Eastern Anatolia

Marmara represents a major pharmaceutical manufacturing and commercial hub due to its concentration of industrial infrastructure, healthcare facilities, pharmaceutical companies, logistics networks, and research capabilities. Istanbul and surrounding industrial areas provide access to skilled professionals, transportation infrastructure, organized industrial zones, and major domestic and international markets.

Central Anatolia also represents an important pharmaceutical region, supported by Ankara's concentration of healthcare institutions, government organizations, universities, and research capabilities. Other regions contribute to pharmaceutical distribution and healthcare demand through expanding healthcare infrastructure and regional population centers.

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the Turkey pharmaceutical market with detailed profiles of major companies, including:

• Abdi İbrahim
• DEVA Holding
• Sanofi
• Novartis
• Pfizer
• Bayer
• Roche
• AstraZeneca
• Nobel İlaç
• Bilim İlaç
• Santa Farma

Domestic pharmaceutical manufacturers are increasingly strengthening their biotechnology, R&D, production, and international expansion capabilities. For example, Abdi İbrahim received accreditation for its AbdiBio R&D Center, supporting its objective of developing and manufacturing biotechnology medicines and biosimilars locally.

DEVA Holding also demonstrates the scale of Turkey's domestic manufacturing ecosystem. Its facilities produced 183 million pharmaceutical boxes at one manufacturing site and 58.18 million boxes at another, while its pharmaceutical logistics center has storage capacity for approximately 43,500 pallets.

What Does The Full Report Cover?

If you are tracking the Turkey pharmaceutical market for investment decisions, market entry planning, competitive benchmarking, or strategic advisory, IMARC Group's report gives you everything in one place:

• Comprehensive market sizing with revenue assessment and market outlook
• Detailed analysis of market drivers, opportunities, challenges, and industry dynamics
• Pharmaceutical drug analysis covering cardiovascular, dermatology, gastrointestinal, genito-urinary, hematology, anti-infective, metabolic, musculoskeletal, central nervous system, oncology, ophthalmology, and respiratory therapies
• Detailed assessment of biologics, including monoclonal antibodies, therapeutic proteins, and vaccines
• Analysis of organic and conventional pharmaceutical products
• Regional assessment covering Marmara, Central Anatolia, Mediterranean, Aegean, Southeastern Anatolia, Black Sea, and Eastern Anatolia
• Competitive landscape covering leading domestic and international pharmaceutical companies
• Analysis of biotechnology, biosimilars, R&D, manufacturing, digitalization, and pharmaceutical supply chain developments
• Assessment of government incentives supporting pharmaceutical manufacturing, R&D, technology transfer, and strategic investments
• Porter's Five Forces analysis and pharmaceutical value chain assessment

Recent News and Developments in Turkey Pharmaceutical Market

• February 2025: Abdi İbrahim received accreditation approval for the R&D Center at its AbdiBio biotechnology pharmaceutical manufacturing facility. The facility focuses on biotechnology medicines and biosimilar development, with the objective of supporting local production and reducing dependency on imported critical medicines.
• September 2025: Biogen and Abdi İbrahim announced a strategic partnership for the distribution of Biogen medicines for neurological and rare diseases in Türkiye. The collaboration aims to improve access to innovative treatments and strengthen the availability of advanced therapies in the country.
• December 2025: Novartis Türkiye opened applications for its "Seninle Olur" program in collaboration with Bilim Virüsü, focusing on young people's self-awareness, professional development, and career skills. The initiative reflects the broader pharmaceutical industry's engagement with talent development and healthcare-related innovation.
• July 2026: DEVA Holding highlighted its integrated pharmaceutical R&D and manufacturing capabilities, including more than 400 expert researchers and activities spanning pharmaceutical APIs, biotechnology, biosimilars, formulation development, and advanced manufacturing.

Key Questions This Report Answers

• What is the current Turkey pharmaceutical market size and what is its market outlook?
• Which type segment represents the largest opportunity in the Turkey pharmaceutical market?
• What are the key factors driving the Turkey pharmaceutical market?
• How are biologics, biosimilars, and biotechnology transforming the Turkish pharmaceutical industry?
• How are government investment incentives supporting pharmaceutical manufacturing and R&D?
• Which regions represent the strongest pharmaceutical manufacturing and consumption opportunities?
• Who are the major companies operating in the Turkey pharmaceutical market?
• How are pharmaceutical companies strengthening local manufacturing and reducing dependence on imported medicines?
• What role will AI, digital healthcare, and advanced manufacturing technologies play in the pharmaceutical industry?
• What are the key investment opportunities across pharmaceutical drugs, biologics, vaccines, and biosimilars?

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104